Share on LinkedInShare on LinkedIn

ARTICLE · 12 DECEMBER 2025

Understanding China's Pharmaceuticals Patent Linkage System: Judicial Trends And Key Takeaways From Recent Cases (Part 2)

Chang Tsi & Partners
Chang Tsi & Partners
Contributor
Chang Tsi & Partners

Chang Tsi & Partners

Chang Tsi & Partners is a "National Outstanding Law Firm (nominated by Ministry of Justice of...

View firm profile
Explore more from Chang Tsi & Partners

In the first article of this series, we elaborated on the regulatory framework of the Pharmaceuticals patent linkage system of China, along with the current status of case acceptance, applicable conditions...

ChinaIntellectual Property

In the first article of this series, we elaborated on the regulatory framework of the Pharmaceuticals patent linkage system of China, along with the current status of case acceptance, applicable conditions, and procedural frameworks. This article turns to emerging judicial rules and practical issues, analyzing how courts and administrative bodies have applied the patent linkage system in actual cases that have been published. Based on the author's experience with such cases, the article offers insights to help practitioners address common challenges.

I. Judicial Rules on Crystalline Form Patents — Patents Not Eligible for Registration

Under China's current patent linkage framework, not all types of drug-related patents are eligible for registration or can serve as the basis for initiating a linkage dispute. Among the more complex issues is how to determine whether a patent is crystalline form patent and whether it falls within the registrable scope. However, in

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from